Incretin-based therapies - review of the physiology, pharmacology and emerging clinical experience
JH Martin, CF Deacon, MD Gorrell, JB Prins
INTERNAL MEDICINE JOURNAL | WILEY | Published : 2011
Diabetes therapies based on manipulation of the incretin system are now widely available, with millions of people receiving treatment. The incretin hormones, glucose-dependent insulinotropic peptide and glucagon-like peptide-1 are released from endocrine cells in the small intestinal mucosa primarily in response to oral nutrient ingestion. They have various effects, but those most relevant to metabolic dysfunction include stimulation of insulin and suppression of glucagon secretion, with resultant reduction in fasting and postprandial glucose. Incretin secretion and/or action is impaired in type 2 diabetes, leading to development of strategies aimed at redressing this abnormality. These stra..View full abstract
Awarded by National Health and Medical Research Council of Australia
JHM: consultancy fees from Bristol-Myers Squibb. CFD: lecture/consultancy fees from Bristol-Myers Squibb, Lilly, Merck, Novartis, Novo Nordisk and Servier; spouse employed by Merck and holds shares in Merck and Novo Nordisk. MDG: consultant, honoraria or indirect benefit from AstraZeneca, Bristol-Myers Squibb, Merck (USA), Merck Sharp & Dohme (Australia), Boehringer Ingelheim (Germany). JBP: lecture/consultancy fees from Merck, Novartis, Novo Nordisk, Eli Lilly; Investigator - Initiated Study support from Merck.M.D.G. is supported by a National Health and Medical Research Council of Australia project grant (518228). Thank you to Professor Lars Erikksson, Herston Medical Library, Royal Brisbane and Women's Hospital, Queensland 4029 for assistance with the literature search.